A Randomized Phase II Trial of Strontium-89 With or Without Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
This study is designed to determine whether the combination of low dose cisplatin and
strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in
hormone refractory prostate cancer.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Palliative pain response
Bernie Eigl, MD
Canada: Health Canada